Treatment of NASH with GLP-1 receptor agonists was reported to ameliorate liver steatosis in both preclinical and clinical studies (Ding et al., 2006; Armstrong et al., 2013). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.